Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1920595

NC1CCN(Cc2ccc(Cl)cc2)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 1/20 0.52
ARG2 P78540 1/20 0.52
SIGMAR1 Q99720 2/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TEAD1 P28347 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
PLA2G7 Q13093 1/20 0.48
MGLL Q99685 1/20 0.48
ABHD6 Q9BV23 1/20 0.48
GAA P10253 1/20 0.48
DPP4 P27487 1/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47
F10 P00742 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1920766 0.89 SIGMAR1 (0.53) SIGMAR1DPP4
Acetic Acid SCHEMBL3958555 0.87 SIGMAR1 (0.54) SIGMAR1MEN1KMT2ATEAD1ALDH1A1
SCHEMBL1021686 0.85 ALDH1A1 (0.60) SIGMAR1MEN1KMT2ATEAD1ALDH1A1
Trifluoroacetic Acid SCHEMBL1921476 0.84 SIGMAR1 (0.55) SIGMAR1MEN1KMT2A
Trifluoroacetic Acid SCHEMBL1920777 0.84 BCHE (0.56) TEAD1ALDH1A1
Hydrochloric Acid SCHEMBL2673496 0.83 MEN1 (0.58) SIGMAR1MEN1KMT2ATEAD1ALDH1A1
Hydrochloric Acid SCHEMBL11533737 0.83 MEN1 (0.58) SIGMAR1MEN1KMT2ATEAD1ALDH1A1
Trifluoroacetic Acid SCHEMBL1921350 0.81 MCHR1 (0.58) SIGMAR1KMT2A
Trifluoroacetic Acid SCHEMBL19613524 0.81 DRD2 (0.49) SIGMAR1MEN1KMT2AALDH1A1DRD2
Trifluoroacetic Acid SCHEMBL19613522 0.81 DRD2 (0.49) SIGMAR1MEN1KMT2AALDH1A1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622914-B1 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS TROVIS PHARMACEUTICALS LLC (US) 2011-06-01 EP disclosed
US-7030240-B2 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2006-04-18 US disclosed
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds HTR5A, HTR2C, HTR1A ARG1 4281/4885ARG2 2329/4885SIGMAR1 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.